Search

Your search keyword '"Karberg, Kirsten"' showing total 110 results

Search Constraints

Start Over You searched for: Author "Karberg, Kirsten" Remove constraint Author: "Karberg, Kirsten" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
110 results on '"Karberg, Kirsten"'

Search Results

1. A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry

2. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network

3. Aktuelle Zahlen zur rheumatologischen Versorgung – Jahresbericht aus der Kerndokumentation der regionalen kooperativen Rheumazentren

4. Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices

7. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

9. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database

10. Current data on rheumatological care: annual report from the National database (NDB) of the regional collaborative arthritis centres in Germany

11. Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres

12. Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices

13. Rheuma- VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.

14. Eine Applikation für die rheumatologische Versorgung: RheCORD

17. Standardpräsentation 2021

18. Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis

19. Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study

20. Die 'ARIAA-Studie' – Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten – klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie

21. B cell characteristics and total numbers predict SARS-CoV-2 vaccination response among patients treated with rituximab

22. Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure

23. Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database

24. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients

25. B Cell Numbers Predict Humoral and Cellular Response Upon SARS – CoV ‐2 Vaccination Among Patients Treated With Rituximab

26. sj-docx-1-tab-10.1177_1759720X221085951 – Supplemental material for Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study

27. sj-docx-1-tab-10.1177_1759720X221114107 – Supplemental material for Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study

28. Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study

29. Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study

30. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients

31. Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?

32. Ist der RAID für entzündlich-rheumatische Erkrankungen ein aussagekräftiges Instrument?

33. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab

34. Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure.

36. Rheuma-VOR: Verbesserung der rheumatologischen Versorgungsqualität durch koordinierte Kooperation - Ein Update

37. Komorbidität und Inanspruchnahme der Gesundheitsversorgung bei Personen mit Sjögren-Syndrom: eine Analyse von Abrechnungsdaten der GKV

40. BENEFIT Study: results of interim analysis of a Pan-European observational study to evaluate real-world effectiveness of SB4 following transition from originator etanercept (ETN) in patients with rheumatoid arthritis (RA) or axial sponyloarthritis (axSpA)

41. Sensitivity and Specificity of Autoantibodies Against CD 74 in Nonradiographic Axial Spondyloarthritis

42. Studienergebnisse der Inter-SpA: Sensitivität und Spezifität von IgA-anti-CD74 bei früher axialer Spondyloarthritis (axSpA)

43. Krankheitsunabhängige Prädiktoren für Fatigue in fünf entzündlich-rheumatischen Erkrankungen

44. Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis.

46. BENEFITS FROM a Plant-Based Diet, Intermittent Fasting and Aspects of Ayurvedic Nutrition IN Rheumatoid Arthritis – a Case Report

48. Bone Loss Is Detected More Frequently in Patients with Ankylosing Spondylitis with Syndesmophytes

49. [With RheMIT rheumatology centers can participate in the German national database-Expansion of the long-term rheumatological documentation].

50. Persistent but atypical germinal center reaction among 3 rd SARS-CoV-2 vaccination after rituximab exposure.

Catalog

Books, media, physical & digital resources